You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Intragam® 10 is indicated for replacement IgG therapy in:
Primary Immunodeficiency Diseases (PID)
Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.
Intragam® 10 is indicated for immunomodulatory therapy in:
Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding
or prior to surgery to correct the platelet count
Kawasaki disease
Guillain-Barre Syndrome (GBS)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multifocal Motor Neuropathy (MMN)
Myasthenia Gravis (MG) in acute exacerbation (myasthenic crisis) or prior to surgery
and/or thymectomy; as maintenance therapy for moderate to severe MG when other
treatments have been ineffective or caused intolerable side effects
Short-term therapy for severely affected nonparaneoplastic
Lambert-Eaton Myasthenic Syndrome (LEMS) patients
Treatment of significant functional impairment in patients who have a verified diagnosis
of stiff person syndrome.
Intragam® 10 is indicated for replacement IgG therapy in:
Primary Immunodeficiency Diseases (PID)
Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.
Intragam® 10 is indicated for immunomodulatory therapy in:
Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding
or prior to surgery to correct the platelet count
Kawasaki disease
Guillain-Barre Syndrome (GBS)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multifocal Motor Neuropathy (MMN)
Myasthenia Gravis (MG) in acute exacerbation (myasthenic crisis) or prior to surgery
and/or thymectomy; as maintenance therapy for moderate to severe MG when other
treatments have been ineffective or caused intolerable side effects
Short-term therapy for severely affected nonparaneoplastic
Lambert-Eaton Myasthenic Syndrome (LEMS) patients
Treatment of significant functional impairment in patients who have a verified diagnosis
of stiff person syndrome.
Intragam® 10 is indicated for replacement IgG therapy in:
Primary Immunodeficiency Diseases (PID)
Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.
Intragam® 10 is indicated for immunomodulatory therapy in:
Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding
or prior to surgery to correct the platelet count
Kawasaki disease
Guillain-Barre Syndrome (GBS)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multifocal Motor Neuropathy (MMN)
Myasthenia Gravis (MG) in acute exacerbation (myasthenic crisis) or prior to surgery
and/or thymectomy; as maintenance therapy for moderate to severe MG when other
treatments have been ineffective or caused intolerable side effects
Short-term therapy for severely affected nonparaneoplastic
Lambert-Eaton Myasthenic Syndrome (LEMS) patients
Treatment of significant functional impairment in patients who have a verified diagnosis
of stiff person syndrome.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
